|
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
RECRUITINGPhase 3Sponsored by Bristol-Myers Squibb
Actively Recruiting
PhasePhase 3
SponsorBristol-Myers Squibb
Started2026-09-08
Est. completion2031-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations37 sites
View on ClinicalTrials.gov →
NCT07680790
Summary
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment * Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution) * Participants must have measurable extracranial disease per RECIST v1.1 as assessed by the investigator * Participants must have ECOG Performance Status 0-1 Exclusion Criteria: * Participants must not have unstable, symptomatic, or uncontrolled CNS metastases, including brain, leptomeningeal disease, and/or spinal cord compression * Participants must not have history of ILD/pneumonitis requiring treatment with steroids (≥ Grade 2), or current or suspected ILD/pneumonitis * Participants must not have clinically significant cardiac disease * Other protocol-defined inclusion/exclusion criteria apply.
Conditions3
CancerLung CancerNon Small Cell Lung Cancer
Interventions5
Locations37 sites
Find trials near these locations
Cancer trials in OrlandoCancer trials in ChicagoCancer trials in BaltimoreCancer trials in OmahaCancer trials in New YorkCancer trials in CharlotteCancer trials in PortlandCancer trials in MemphisCancer trials in DallasCancer trials in San AntonioCancer trials in SeattleLung Cancer trials in OrlandoAll trials in CaliforniaAll trials in ColoradoAll trials in FloridaAll trials in IllinoisAll trials in MarylandAll trials in MinnesotaAll trials in MissouriAll trials in NebraskaAll trials in New HampshireAll trials in New JerseyAll trials in New YorkAll trials in North CarolinaAll trials in OhioAll trials in OregonAll trials in PennsylvaniaAll trials in South DakotaAll trials in TennesseeAll trials in TexasAll trials in UtahAll trials in VirginiaAll trials in WashingtonAll trials in West Virginia
Related trials
- A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors — Mabwell (Shanghai) Bioscience Co., Ltd.
- A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer — Shanghai Jiao Tong University School of Medicine
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer — Xianglin Yuan
- A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy — Tianjin Medical University Cancer Institute and Hospital
- A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer — Qilu Pharmaceutical Co., Ltd.
- A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies — First Affiliated Hospital of Fujian Medical University
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) — Sichuan Baili Pharmaceutical Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorBristol-Myers Squibb
Started2026-09-08
Est. completion2031-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations37 sites
View on ClinicalTrials.gov →
NCT07680790